Several studies, have indicated that SET-binding peptides such as COG112 and OP449 inhibit the interplay between SET and PP2A, block malignant progression and reduce phosphorylation of tau in AD mouse models, providing a proof of concept that targeting SET might represent a new therapeutic approach for cancer and AD. Here, MAPT is linked to Alzheimer disease.